It depends on the technology for the vaccine, but for the mRNA vaccine, one of the benefits is that it can be easily adjusted, and to different variants, should that be a need.
Just on that point, we know that a whole suite of vaccine manufacturers are already looking at different vaccines that are more adapted to some of the variants that have been picked up globally. That study is already taking place and we expect that to be quite fast.